Does Fallon Community Health Plan (FCHP) Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia is the brand name for denosumab, a human monoclonal antibody that inhibits RANK ligand (RANKL), a protein that activates osteoclasts. By blocking osteoclast activity, denosumab reduces bone resorption and increases bone mineral density (BMD). The FDA approved Prolia in June 2010 for postmenopausal women at high fracture risk, and later for men with osteoporosis, patients on long-term glucocorticoids, and patients experiencing bone loss from aromatase inhibitor or androgen deprivation therapy. The prescribing information is publicly available through the FDA's drug database. [1]

Clinical Evidence Supporting Prolia Use

The key FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months. [2] These figures come directly from the primary efficacy endpoint published in the New England Journal of Medicine.

The FREEDOM Extension study followed participants for up to 10 years and showed continued BMD gains at the lumbar spine and total hip with long-term denosumab use, without evidence of a therapeutic plateau. [3] That extended data set is one reason endocrinologists and rheumatologists now consider denosumab a long-term option rather than only a second-line agent.

Guidelines That Support Coverage Justification

The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines for osteoporosis designate denosumab as a first-line agent for patients at very high fracture risk, defined as a FRAX 10-year major osteoporotic fracture probability exceeding 20% or a prior fragility fracture. [4] Insurers including FCHP frequently reference AACE criteria when evaluating prior authorization requests.

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women also supports denosumab as a primary option, particularly when oral bisphosphonates are contraindicated due to renal impairment (eGFR <35 mL/min/1.73m²). [5]

How FCHP Structures Drug and Biologics Coverage

FCHP is a Massachusetts-based health plan offering commercial, Medicare Advantage, and MassHealth (Medicaid managed care) products. Prolia, because it is an injected biologic administered in a physician's office, is almost always covered under the medical benefit rather than the pharmacy benefit. This distinction changes how the claim is filed and how cost-sharing applies.

Medical Benefit vs. Pharmacy Benefit

When a drug is billed under the medical benefit, the provider submits a claim using a J-code. Prolia's HCPCS code is J0897 (denosumab injection, 1 mg; a 60 mg dose = 60 units). The patient's medical deductible and coinsurance apply, not the prescription copay tier. For many FCHP commercial members, this means Prolia falls under the specialist or outpatient infusion cost-sharing structure.

Plans that allow self-administration at home may route Prolia through the pharmacy benefit, but this is uncommon because denosumab requires refrigeration and injection technique training.

Prior Authorization Criteria FCHP Typically Applies

Most FCHP plan documents require prior authorization for Prolia. Criteria commonly include the following items, each of which must be documented in the medical record:

• A diagnosis of osteoporosis confirmed by DXA scan showing T-score of -2.5 or lower, OR a prior fragility fracture, OR a T-score between -1.0 and -2.5 (osteopenia) combined with a FRAX score meeting high-risk thresholds.
• Documentation that the prescribing physician is an appropriate specialist (endocrinologist, rheumatologist, or primary care physician with documented osteoporosis management experience).
• Step-therapy compliance: evidence that the patient has tried and failed, or has a documented contraindication to, an oral bisphosphonate such as alendronate. Contraindications include esophageal disorders, inability to sit upright for 30 minutes, or eGFR <35 mL/min/1.73m².
• For glucocorticoid-induced osteoporosis: documentation of systemic steroid use at prednisone-equivalent doses of 5 mg/day or more for 3 months or longer. [6]

FCHP Medicare Advantage and Prolia Coverage

For members enrolled in an FCHP Medicare Advantage plan, the coverage pathway mirrors original Medicare rules in many respects. Under original Medicare Part B, Prolia administered in a physician's office is covered at 80% of the Medicare-approved amount after the Part B deductible, provided the claim meets medical necessity criteria. FCHP Medicare Advantage plans generally replicate this benefit structure, though specific cost-sharing may differ.

Medicare National Coverage Determination

CMS has not issued a standalone National Coverage Determination (NCD) specifically for denosumab, but coverage flows through Part B's general coverage of drugs incident to a physician's service. CMS guidance on injectable osteoporosis drugs under Part B outlines that FDA-approved bone agents, including denosumab, are covered for eligible diagnoses. [7]

What Medicare Advantage Adds

FCHP Medicare Advantage plans may impose their own formulary management tools on top of Medicare's baseline. These may include concurrent review, quantity limits tied to the every-6-months dosing schedule, and step-therapy edits requiring a bisphosphonate trial. The Medicare Improvements for Patients and Providers Act and subsequent CMS guidance limit some step-therapy requirements on Medicare Advantage plans for biologics, but insurers retain authority to apply medically appropriate utilization management. [8]

Patients covered under FCHP's Senior Care Options (SCO), which integrates Medicare and MassHealth, should confirm whether Prolia is managed through the medical or pharmacy side of that dual-eligible product, as routing differs by contracted pharmacy benefit manager.

How to Obtain Prior Authorization for Prolia Through FCHP

Getting prior authorization approved on the first submission reduces treatment delays and avoids the months-long gap in denosumab therapy that sharply increases rebound fracture risk. A study published in the Journal of Bone and Mineral Research found that patients who discontinued denosumab without transitioning to a bisphosphonate experienced rapid BMD loss and multiple vertebral fractures within 12 to 24 months. [9] That risk makes authorization efficiency a clinical priority, not just an administrative one.

Step 1: Confirm DXA Documentation

The prescribing physician should have a DXA report in the chart showing site-specific T-scores and, where applicable, a FRAX calculation. FCHP reviewers will look for numerical T-scores, not just a narrative that says "osteoporosis." Lumbar spine and femoral neck T-scores should be listed separately.

Step 2: Document Bisphosphonate History or Contraindication

If the patient has previously taken alendronate, risedronate, or another oral bisphosphonate, the chart should note the duration of therapy, the reason for discontinuation, and any adverse effects such as esophageal irritation or osteonecrosis of the jaw risk. If step therapy is being waived due to contraindication, a specific clinical rationale linked to the patient's comorbidities should be documented. Renal impairment with eGFR <35 mL/min/1.73m² is the most commonly accepted contraindication, consistent with FDA labeling. [1]

Step 3: Submit the Prior Authorization with Clinical Notes

Submitting a bare PA form without attached clinical notes is the most common reason for initial denials. The PA package should include the DXA report, the most recent FRAX score printout if applicable, office notes documenting the clinical decision rationale, and any specialist letters. FCHP's provider portal accepts electronic PA submissions.

Step 4: Request Peer-to-Peer Review if Denied

If the initial authorization is denied, the prescribing physician has the right to request a peer-to-peer phone call with the FCHP medical reviewer. This call gives the clinician an opportunity to clarify clinical nuances that the written record may not have conveyed. Peer-to-peer reviews reverse initial denials in a meaningful proportion of cases.

What to Do if FCHP Denies Prolia Coverage

A denial is not a final answer. Federal and Massachusetts state law give members specific rights to appeal.

Internal Appeal

The first step is filing an internal (Level 1) appeal with FCHP within the timeframe specified in the denial letter, typically 60 to 180 days from the denial date. The appeal should include a physician letter explicitly addressing each criterion listed in the denial reason, additional clinical evidence such as fracture history or bone turnover marker results, and references to current guidelines. The AACE 2020 guidelines [4] and the Endocrine Society 2019 guidelines [5] are directly citable in appeal letters because FCHP's medical policies often reference these same organizations.

External Appeal

Massachusetts law grants members the right to an external Independent Medical Review (IMR) if the internal appeal is denied. The external reviewer is an independent board-certified physician with no financial relationship with FCHP. IMR decisions are binding on the insurer for medical necessity determinations. The Massachusetts Division of Insurance oversees this process.

Expedited Appeal for Urgent Cases

Patients already on denosumab who face a treatment gap because of a coverage dispute may request an expedited appeal, which must be resolved within 72 hours under federal managed care rules. Given the fracture rebound data from the Journal of Bone and Mineral Research [9], a treating physician can credibly argue that a dosing gap constitutes an urgent clinical risk.

Prolia Patient Assistance and Cost-Share Programs

If coverage is denied and appeals are exhausted, or while an appeal is pending, several financial assistance pathways exist.

Amgen Assist 360

Amgen, the manufacturer of Prolia, operates the Assist 360 program, which includes co-pay assistance cards for commercially insured patients and a free-drug program (Amgen Safety Net Foundation) for uninsured or underinsured patients meeting income criteria. Eligibility and benefit amounts change periodically, and the current program terms are available directly through Amgen. Co-pay cards typically cannot be used by Medicare or Medicaid beneficiaries due to federal anti-kickback rules.

Massachusetts Prescription Drug Programs

Massachusetts operates several state-funded drug assistance programs, including the Prescription Advantage program historically administered through the Executive Office of Elder Affairs, which has helped older residents with cost sharing on expensive medications. Eligibility is income-based. Patients denied FCHP coverage may benefit from connecting with a Massachusetts State Health Insurance Assistance Program (SHIP) counselor, who can review all available options at no charge.

Alternatives to Prolia That FCHP May Cover More Readily

If step therapy or coverage barriers make Prolia inaccessible in the near term, several other osteoporosis agents may be covered under FCHP formularies with fewer prior authorization hurdles.

Oral Bisphosphonates

Alendronate (generic) and risedronate (generic) are available for under $15 per month at most pharmacies and are covered on virtually every formulary at Tier 1 or Tier 2. The key FIT trial demonstrated that alendronate 10 mg daily reduced morphometric vertebral fractures by 47% over 3 years in women with osteoporosis. [10] These agents remain first-line per AACE guidelines and serve as the required step-therapy agent before Prolia in most FCHP PAs.

Zoledronic Acid (Reclast)

Zoledronic acid 5 mg IV once yearly is an alternative for patients who cannot tolerate oral bisphosphonates. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in morphometric vertebral fractures at 3 years with zoledronic acid compared with placebo. [11] This agent is also billed under the medical benefit (J3489) and requires PA, but its annual dosing simplifies the coverage review cycle compared with every-6-months denosumab.

Romosozumab (Evenity) and Teriparatide (Forteo)

For very high-risk patients, anabolic agents such as romosozumab 210 mg monthly (12 doses) or teriparatide 20 mcg daily (up to 24 months) may be covered. Both require prior authorization and carry higher list prices. Romosozumab carries an FDA boxed warning for cardiovascular events, and FCHP reviewers will look for documentation that cardiac risk has been assessed before approving it. [12] The FDA label for teriparatide imposes a lifetime duration limit of 24 months due to osteosarcoma risk data from rat studies, a restriction that FCHP's coverage policy mirrors. [13]

Special Populations and Prolia Coverage Considerations

Men with Osteoporosis

Prolia is FDA-approved for men with osteoporosis at high fracture risk. Coverage criteria for men parallel those for women, requiring DXA-documented T-score thresholds and bisphosphonate step therapy unless contraindicated. A Phase 3 study in men (N=242) demonstrated that denosumab 60 mg every 6 months increased lumbar spine BMD by 5.7% versus 0.9% with placebo at 12 months. [14] FCHP reviewers may apply more scrutiny to male patients simply due to lower overall prevalence of osteoporosis in that population.

Cancer Patients Receiving Hormone Therapy

Patients undergoing androgen deprivation therapy (ADT) for prostate cancer or aromatase inhibitor therapy for breast cancer are at elevated fracture risk. Prolia is FDA-approved for these indications. [1] FCHP oncology benefit reviews sometimes handle these cases separately from standard osteoporosis PAs, because the prescribing oncologist rather than a bone specialist initiates the request. Oncologists submitting PAs for these patients should include documentation of the cancer diagnosis, the hormone therapy regimen, the patient's current BMD, and the fracture risk calculation.

Glucocorticoid-Induced Osteoporosis

Systemic corticosteroid use is one of the most common secondary causes of osteoporosis. The American College of Rheumatology 2022 guidelines recommend pharmacologic therapy for patients over age 40 taking prednisone-equivalent doses of 2.5 mg/day or more for 3 or more months who have a high or moderate fracture risk. [6] Denosumab is listed as an option in those guidelines, particularly when renal impairment precludes bisphosphonate use. FCHP reviewers are generally familiar with ACR guidelines, making them a useful reference in PA submissions for this patient group.

Monitoring Requirements and Ongoing Coverage

Prolia is dosed every 6 months, meaning coverage must be reauthorized periodically. Most FCHP plans require annual reauthorization even though the drug is given twice yearly. Each reauthorization cycle should include updated clinical notes confirming that the patient is tolerating therapy, that no new contraindications (such as hypocalcemia or serious infection) have emerged, and ideally a DXA showing BMD response. The FDA label recommends monitoring serum calcium before each dose due to risk of hypocalcemia, particularly in patients with renal impairment. [1] Adequate calcium and vitamin D supplementation is required before and during denosumab therapy.

A 2022 analysis published in JAMA Internal Medicine found that among Medicare beneficiaries who initiated denosumab, approximately 33% experienced a treatment gap exceeding 7 months between injections, substantially elevating rebound fracture risk. [15] Proactive reauthorization submission, at least 60 days before the next scheduled dose, reduces the likelihood of a coverage-related gap.